Volastra Therapeutics

Edit info

Founded: 2020

Location: New York, NY

Employee range: 11 - 50

Clinical stage: Clin1

Therapy area: Multiple cancers

Drug types: ONC

Lead product: Sovilnesib

Funding: $60M A Mar 2023; $32M seed Apr 2021; $12M seed Sep 2020

Investors: Vida Ventures, Catalio Capital Management, Polaris Partners, Droia Ventures, Arch Venture Partners, Quark Venture, Cornell University

volastratx.com

linkedin.com

job board

Business:

Therapies for the treatment of metastatic cancers

Drug notes:

VLS-1488 Clin0 oncology; 2 undisclosed programs RD oncology

About:

Volastra Therapeutics is developing drugs that target a vulnerability of cancer cells - chromosomal instability, or CIN. CIN is present in 60-80% of cancers and is associated with poor survival in many patients. By using their proprietary CINtech platform that incorporates cancer biology, data sciences and medicinal chemistry, Volastra is turning a deep biological understanding of CIN into life-saving therapies. The tools Volastra is using range from CIN CRISPR screen, CIN imaging and genomics to molecular structure-activity analysis. Volastra is initially focusing on two therapeutic approaches: synthetic lethality and immune activation, with programs in early development.